Rickets - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for rickets including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for rickets

Rickets is a skeletal disorder occurring due to the deficiency of vitamin D, calcium, or phosphate. There are important nutrients for the development of strong and healthy bones. People with rickets generally have weak and soft bones, stunted growth, and skeletal deformities. It is the most common disease in children aged between 6 and 36 months. Children with rickets might not get enough vitamin D if they live in a region with low sunlight, follow a vegetarian diet or do not consume milk products. Vitamin D facilitates the absorption of calcium and phosphate in the small intestine.  A vitamin D deficiency makes it difficult for the human body to maintain sufficient levels of calcium and phosphate. During this situation, the body produces hormones that release calcium and phosphate from the bones, which makes them weak and soft.  The disease is rare in developed and developing countries due to the introduction of fortified foods such as cereals with added vitamin D. In areas such as Africa, some parts of Asia, and South America, the incidence and prevalence rates of rickets are very high owing to the lack of nutritional food. Furthermore, in most of the industrialized countries, the prevalence of rickets in general population reduced after the introduction of clean-air legislation and dietary supplementation. Consequently, the rising incidences of rickets in the emerging economies is expected to promote the drug development for rickets in the forthcoming years.

According to this pipeline analysis report, almost half of the drug molecules in the pipeline are being developed for autosomal recessive hypophosphatemic rickets type 2 (ARHR2) and rest half for X-linked hypophosphatemia (XLH). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of rickets. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Kyowa Hakko Kirin
• Inozyme Pharma

Therapeutic assessment of the drug development pipeline for rickets by route of administration

• Subcutaneous

The subcutaneous route of administration (ROA) involves the application of the drug directly into the layer of the skin below the dermis and the epidermis, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for rickets by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for rickets are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for rickets?
• What are the companies that are currently involved in the development of drug molecules for rickets?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.